ResMed, Inc.

Equities

RMD

US7611521078

Advanced Medical Equipment & Technology

Market Closed - Nyse Other stock markets 04:00:04 2024-04-23 pm EDT			5-day change	1st Jan Change
184.2 ^USD	+2.16%		-0.33%	+7.11%

Apr. 17	Wall St set for higher open on megacaps boost; earnings, Fed comments on tap	RE
Apr. 01	Needham Adjusts ResMed's Price Target to $224 From $180, Maintains Buy Rating	MT

ResMed Inc. Reports Earnings Results for the First Quarter Ended September 30, 2021

October 29, 2021 at 06:15 am EDT

ResMed Inc. reported earnings results for the first quarter ended September 30, 2021. For the first quarter, the company reported revenue was USD 904.02 million compared to USD 751.94 million a year ago. Net income was USD 203.61 million compared to USD 178.37 million a year ago. Basic earnings per share from continuing operations was USD 1.4 compared to USD 1.23 a year ago. Diluted earnings per share from continuing operations was USD 1.39 compared to USD 1.22 a year ago.

Latest news about ResMed, Inc.

Wall St set for higher open on megacaps boost; earnings, Fed comments on tap	Apr. 17	RE
Needham Adjusts ResMed's Price Target to $224 From $180, Maintains Buy Rating	Apr. 01	MT
ResMed Inc. Announces the U.S. Launch of the AirFit F40	Mar. 06	CI
Morgan Stanley Adjusts Resmed’s Price Target to AU$31.80 From AU$28.60, Keeps at Overweight	Mar. 05	MT
Evans & Partners Upgrades ResMed to Positive From Neutral, Price Target is AU$31	Mar. 04	MT
FTSE 100 Edges Higher on Leap Day, Boosted by Howden Joinery, Haleon Gains	Feb. 29	DJ
Australia shares slip as biotech firm CSL slumps on failed drug trial (Feb 12)	Feb. 11	RE
Powell, the paper tiger	Feb. 05
ANALYST RECOMMENDATIONS : Abbvie, Microsoft, Tesla, Alphabet, Booking...	Feb. 05
Mizuho Adjusts Price Target on ResMed to $215 From $195, Keeps Buy Rating	Jan. 30	MT
Oppenheimer Raises ResMed Price Target to $205 From $185, Maintains Outperform Rating	Jan. 30	MT
UBS Adjusts ResMed Price Target to $180 From $175, Maintains Neutral Rating	Jan. 25	MT
Sector Update: Health Care Stocks Mixed Pre-Bell Thursday	Jan. 25	MT
Oppenheimer Raises ResMed Price Target to $185 From $175, Maintains Outperform Rating	Jan. 25	MT
RBC Lifts Price Target on ResMed to $182 From $181, Cites 'Solid' Fiscal Q2 Results, Keeps Sector Perform Rating	Jan. 25	MT
ResMed Fiscal Q2 Non-GAAP Earnings, Revenue Increase; Shares Rise Premarket	Jan. 25	MT
ResMed Posts Lower Fiscal Q2 Profit; Shares Up 7%	Jan. 24	MT
ResMed Declares Q4 Dividend; Shares Jump 7%	Jan. 24	MT
ResMed beats estimates on strong sleep apnea device sales	Jan. 24	RE
ResMed Resumes Share Buyback Program With $50 Million of Repurchases in Fiscal Q2	Jan. 24	MT
ResMed Keeps Quarterly Cash Dividend at $0.48 a Share, Payable March 14 to Holders of Record Feb. 8	Jan. 24	MT
ResMed Fiscal Q2 Non-GAAP Earnings, Revenue Increases; Shares Jump After-Hours	Jan. 24	MT
ResMed Inc. Declares Quarterly Cash Dividend, Payable on March 14, 2024	Jan. 24	CI
Transcript : ResMed Inc., Q2 2024 Earnings Call, Jan 24, 2024	Jan. 24
Tranche Update on ResMed Inc.'s Equity Buyback Plan announced on February 27, 2014.	Jan. 24	CI

Chart ResMed, Inc.

Duration

Period

More charts

Company Profile

ResMed, Inc. specializes in designing, manufacturing and marketing respiratory disorders diagnosis, treatments and management (primarily sleep respiratory disorders). Net sales break down by family of products as follows: - medical devices (50.4%); - masks (37.9%); - software as a service (11.7%). At the end of June 2021, the group had 6 production sites located in the United States (2), Australia, China, Singapore and Malaysia. The United States accounts for 61.4% of net sales.

Sector

Advanced Medical Equipment & Technology

Calendar

2024-04-25 - Q3 2024 Earnings Release

Related indices

S&P 500

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

ResMed, Inc. continues to make headway in the sleep market

December 11, 2023 at 05:55 am EST

More Strategies

Ratings for ResMed, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

184.2 USD

Average target price

206.1 USD

Spread / Average Target

+11.85%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Advanced Medical Equipment & Technology

	1st Jan change	Capi.
RESMED, INC.	+7.11%	27.06B
THERMO FISHER SCIENTIFIC	+8.35%	219B
DANAHER CORPORATION	+9.41%	187B
INTUITIVE SURGICAL, INC.	+11.75%	134B
BOSTON SCIENTIFIC CORPORATION	+19.34%	101B
SIEMENS HEALTHINEERS AG	-0.38%	62.27B
EDWARDS LIFESCIENCES CORPORATION	+15.08%	52.82B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	-2.10%	47.49B
AGILENT TECHNOLOGIES, INC.	+0.10%	40.79B
GE HEALTHCARE TECHNOLOGIES INC.	+11.50%	39.35B

Other Advanced Medical Equipment & Technology